Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
复制标题

DOI:
10.2217/pgs.09.82
复制
发表时间:
2009-09
期刊:
影响因子:
2.1
通讯作者:
Aquilante CL
Aquilante CL
中科院分区:
医学4区
文献类型:
--
作者:
Daily EB;Aquilante CL

文献摘要

参考文献

被引文献

相似文献

Cytochrome P450 (CYP) 2C8 is responsible for the oxidative metabolism of many clinically available drugs from a diverse number of drug classes (e.g., thiazolidinediones, meglitinides, NSAIDs, antimalarials and chemotherapeutic taxanes). The CYP2C8 enzyme is encoded by the CYP2C8 gene, and several common nonsynonymous polymorphisms (e.g., CYP2C8*2 and CYP2C8*3) exist in this gene. The CYP2C8*2 and *3 alleles have been associated in vitro with decreased metabolism of paclitaxel and arachidonic acid. Recently, the influence of CYP2C8 polymorphisms on substrate disposition in humans has been investigated in a number of clinical pharmacogenetic studies. Contrary to in vitro data, clinical data suggest that the CYP2C8*3 allele is associated with increased metabolism of the CYP2C8 substrates, rosiglitazone, pioglitazone and repaglinide. However, the CYP2C8*3 allele has not been associated with paclitaxel pharmacokinetics in most clinical studies. Furthermore, clinical data regarding the impact of the CYP2C8*3 allele on the disposition of NSAIDs are conflicting and no definitive conclusions can be made at this time. The purpose of this review is to highlight these clinical studies that have investigated the association between CYP2C8 polymorphisms and CYP2C8 substrate pharmacokinetics and/or pharmacodynamics in humans. In this review, CYP2C8 clinical pharmacogenetic data are provided by drug class, followed by a discussion of the future of CYP2C8 clinical pharmacogenetic research.
DOI: 10.2217/14622416.8.2.187
发表时间: 2007-03
期刊: Pharmacogenomics
影响因子: 2.1
作者:
Gil JP;Gil Berglund E
通讯作者: Gil Berglund E
DOI: 10.1046/j.0306-5251.2003.01862.x
发表时间: 2003-09-01
影响因子: 3.4
作者:
Bidstrup, TB;Bjornsdottir, I;Hansen, KT
通讯作者: Hansen, KT
DOI: 10.1124/dmd.106.012823
发表时间: 2007-04-01
影响因子: 3.9
作者:
DeLozier, Tracy C.;Kissling, Grace E.;Goldstein, Joyce A.
通讯作者: Goldstein, Joyce A.
DOI: 10.1097/00008571-200110000-00006
发表时间: 2001-10-01
期刊: PHARMACOGENETICS
影响因子: --
作者:
Dai, D;Zeldin, DC;Goldstein, JA
通讯作者: Goldstein, JA
DOI: 10.1124/mol.105.013169
发表时间: 2005-09-01
影响因子: 3.6
作者:
Ferguson, SS;Chen, YP;Goldstein, JA
通讯作者: Goldstein, JA